iRhythm Technologies Securities Class Action
iRhythm Technologies · Zio AT heart monitoring device · Settlement Reached
About this case
Purchasers of iRhythm Technologies common stock alleged that the company and its chief executive made materially false or misleading statements or omissions concerning the Zio AT heart monitoring device, in violation of federal securities laws. The parties reached a proposed $45 million cash settlement, which remained subject to final court approval at the time described.
Case overview
- Defendant company
- iRhythm Technologies
- Product or service
- Zio AT heart monitoring device
- Court case number
- 3:24-CV-706-JSC
- Case status
- Settlement Reached
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- iRhythm Securities Litigation Settlement Claim
Participation information
iRhythm Securities Litigation Settlement Claim
Generally, persons or entities who purchased or acquired iRhythm Technologies common stock between 2022-07-25 and 2024-08-09, inclusive, and were allegedly damaged, excluding persons and entities specified in the official notice, may be eligible.
Complete and sign the Proof of Claim and Release Form, then submit it online through the settlement website or mail it to Strategic Claims Services at iRhythm Securities Litigation, P.O. Box 230, 600 N. Jackson St., Ste. 205, Media, PA 19063. Online submissions must be received, and mailed claims postmarked, no later than 2026-10-01.
- Type
- Settlement Claim
- Status
- Open
- Total settlement amount
- $45,000,000
- Payout
- Eligible approved claims will receive a pro rata share of the net settlement fund under the court-approved plan of allocation. Individual recoveries vary based on factors including eligible transactions and the number of valid claims; the official notice estimates approximately $1.83 per eligible share before deductions, but that is not a guaranteed payment amount.
- Reported proof requirement
- Yes
Sources
- iRhythm Securities Class Action Settlement
Barchart.com ·